Australia is closely awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://aliviagnsm779641.wikistatement.com/5897150/retatrutide_australia_a_potential_solution_for_obesity_treatment